During the past decade, Element Research Group conducted 5 clinical trials. In the 10-year time frame, 5 clinical trials started and 3 clinical trials were completed, i.e. on average, 60% percent of trials that started reached the finish line to date. In the past 5 years, 2 clinical trials started and 3 clinical trials were completed. i.e. 150% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Element Research Group" #1 sponsor was "Baxalta now part of Shire" with 1 trials, followed by "Brigham and Women's Hospital" with 1 trials sponsored, "Integra LifeSciences Corporation" with 1 trials sponsored, "Regeneron Pharmaceuticals" with 1 trials sponsored and "Revance Therapeutics, Inc." with 1 trials sponsored. Other sponsors include -4 different institutions and companies that sponsored additional 6 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Element Research Group" #1 collaborator was "Baxalta Innovations GmbH, now part of Shire" with 1 trials as a collaborator, "Iqvia Pty Ltd" with 1 trials as a collaborator, "National Heart, Lung, and Blood Institute (NHLBI)" with 1 trials as a collaborator and "Sanofi" with 1 trials as a collaborator. Other collaborators include -4 different institutions and companies that were collaborators in the rest 4 trials.

According to Clinical.Site data, the most researched conditions in "Element Research Group" are "Chronic Obstructive Pulmonary Disease" (2 trials), "Alpha1-antitrypsin Deficiency" (1 trials), "Asthma" (1 trials), "Cardiovascular Disease" (1 trials) and "Diabetic Foot Ulcer" (1 trials). Many other conditions were trialed in "Element Research Group" in a lesser frequency.

Most popular intervention types in "Element Research Group" are "Drug" (3 trials), "Biological" (2 trials) and "Device" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (3 trials), "ARALAST NP 120 mg/kg" (1 trials), "ARALAST NP 60 mg/kg" (1 trials), "Botulinum Toxins, Type A" (1 trials) and "DUPIXENT®" (1 trials). Other intervention names were less common.

The vast majority of trials in "Element Research Group" are 6 trials for "All" genders.

Currently, there are NaN active trials in "Element Research Group". undefined are not yet recruiting, 1 are recruiting, undefined are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in Element Research Group, undefined suspended trials, and 1 terminated clinical trials to date.

Out of the total trials that were conducted in Element Research Group, 0 "Phase 1" clinical trials were conducted, 1 "Phase 2" clinical trials and 3 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 1 trials that are defined as “Not Applicable".